Atopic Dermatitis
main-banner
Atopic Dermatitis
LP0133-1426 Enrolling

Adolescent Chronic Hand Eczema Research Study (CHE) (22 Weeks)


Treatment: Topical Age: 12 Years


Who Can Participate?

Adolescents aged 12 to 17 diagnosed with CHE that has persisted for more than 3 months or returned twice or more within the last 12 months

Inclusion Criteria 

  • Not having concurrent skin diseases on the hands, e.g. tinea manuum
  • Subjects who have a documented recent history of inadequate response to treatment with TCS
  • Subjects’ adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens
  • Not having active psoriasis on any part of the body

What Are The Benefits? 

  • No cost to participate or receive treatment
  • Regular visits with study doctors who specialize in treating CHE (8 visits)
  • Will receive topical treatment in the form of a cream

How Long Will The Study Last?

  • Around 22 weeks

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Firouzeh Niakosari

Dermatologist

Dr. Marisa Ponzo

Dermatologist

Dr. Jaggi Rao

Dermatologist

Dr. Irina Turchin

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 23, 2024

Official Title

A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

ClinicalTrials.gov ID

NCT05355818

Sponsor

LEO Pharma

Study Description

  • Brief Summary:

    The purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (CHE) and what side effects it may have, in children aged 12-17. There will be a range of assessments that rate the severity and extent of CHE symptoms, general health and quality of life. Delgocitinib is a cream that suppresses specific processes in the body's response to diseases like CHE, such as inflammation. The trial will last up to 22 weeks and has a 1-4 week screening period, a 16 week treatment period and a 2 week follow up period. During the treatment period each child will use either delgocitinib cream or a cream vehicle twice a day. Which cream each child receives is chosen randomly by a computer. The cream vehicle is made of the same ingredients as the delgocitinib cream except for the active medical ingredient. There will be 8 visits with the trial doctor.

  • Condition or Disease:

    Chronic Hand Eczema

  • Intervention/Treatment:

    Drug: Delgocitinib
    Drug: Cream vehicle
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    12 Years and 17 Years (Child)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE.
Subjects who have a documented history of inadequate response to treatment with TCS or for whom TCS are documented to be otherwise medically inadvisable.

Exclusion Criteria:

Concurrent skin disease on the hands.
Clinically significant infection on the hands.
Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline.
Previous or current treatment with JAK inhibitors (including delgocitinib/LEO 124249), systemic or topical.
Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline.
Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
Other cutaneously applied therapy on the hands (except for the use of subject’s own emollients) within 7 days prior to baseline.
Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.

Any disorder which is not stable and could:

Affect the safety of the subject throughout the trial.
Impede the subject’s ability to complete the trial.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Atopic Dermatitis

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content